---
title: "\"Profit Alert\" RemeGen's revenue increased by 89%, forecasting an annual profit of over 700 million RMB"
description: "RemeGen released a positive profit forecast, expecting a net profit of approximately 716 million RMB for the fiscal year 2025, compared to a loss of 1.468 billion RMB in the previous year. The turnaro"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274419093.md"
published_at: "2026-02-01T10:57:12.000Z"
---

# "Profit Alert" RemeGen's revenue increased by 89%, forecasting an annual profit of over 700 million RMB

> RemeGen released a positive profit forecast, expecting a net profit of approximately 716 million RMB for the fiscal year 2025, compared to a loss of 1.468 billion RMB in the previous year. The turnaround from loss to profit is mainly attributed to the rapid growth of core products Teprotumumab and Vadastuximab, as well as increased technology licensing revenue from collaboration with Vor BioPharma Inc. The company reduced costs by optimizing management and production processes, with an annual operating revenue of approximately 3.25 billion RMB, an increase of 89%

RemeGen (09995.HK) issued a profit warning, expecting a net profit of approximately RMB 716 million for the fiscal year 2025, compared to a loss of RMB 1.468 billion in the previous year. The turnaround from loss to profit is mainly due to the rapid growth in domestic sales revenue of core products Tislelizumab and Vadastuximab, which have become the core growth engines of the performance; at the same time, the company successfully reached a significant cooperation, granting Vor Biopharma Inc. the development and commercialization rights for Tislelizumab, resulting in a substantial increase in technology licensing revenue. In addition, through management optimization and iterative production processes, the company has reduced unit production costs and improved product gross margins. The total operating revenue for the year is approximately RMB 3.25 billion, an increase of 89%

### Related Stocks

- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [560600.CN - Founder Fubon CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/560600.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [688331.CN - RemeGen](https://longbridge.com/en/quote/688331.CN.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [09995.HK - REMEGEN](https://longbridge.com/en/quote/09995.HK.md)
- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) |
| RemeGen Lifts Price Cap on Share Repurchase | RemeGen Lifts Price Cap on Share Repurchase | [Link](https://longbridge.com/en/news/272783447.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Elon Musk’s Neuralink sparks BCI race in China | Neuralink, founded by Elon Musk, is driving a surge in brain-computer interface (BCI) development in China, with startup | [Link](https://longbridge.com/en/news/276460367.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.